For several years, Prof. Bernard Hanseeuw and the Kienlen-Campard labs have been collaborating with Cliniques Universitaires Saint-Luc to establish a biobank of plasma and cerebrospinal fluid. The goal is to discover new early biomarkers for Alzheimer’s disease and related dementias. Over the past four years, samples have been collected from both volunteer participants and Alzheimer’s patients, totaling more than 400 participants. Half of the participants were followed over the years with cognitive assessment and brain imaging acquisitions (Amyloid PET, Tau PET, MRI).